Background: Intracerebral hemorrhage is a devastating clinical event, and secondary prevention is pivotal to avoid further cerebral complications, but no clear guidance exist for selecting high-risk patients. The CHA2DS2-VASc score is a widespread tool to assess the risk of stroke among patients with atrial fibrillation (AF). Objectives: We investigated the ability of the CHA2DS2-VASc score for estimating cerebrovascular ischemic events in patients with recent intracerebral hemorrhage with or without comorbid AF. Methods: Patients with a diagnosis of intracerebral hemorrhage between 2003 and 2018 were considered for inclusion. Four registries were linked to obtain individual-level information, and included patients were followed for the occurrence of cerebrovascular ischemic events and all-cause mortality. We report absolute risks at 5 years stratified by baseline CHA2DS2-VASc score and AF prevalence. Results: The study included 12,245 patients (46.4% females) of whom 19% had prevalent AF. Patients without AF were younger (mean age: 70 vs. 78 years) and had a lower CHA2DS2-VASc score (2.5 vs. 3.6). The overall 5-year risk of cerebrovascular ischemic events was 5.2% (95% CI 4.7–5.6) for patients without AF and 7.3% (95% CI 6.0–8.5) for AF patients; all-cause mortality was higher than 30 and 50% in patients without or with AF, respectively. The predictive performance of the CHA2DS2-VASc score was poor with c-statistics around 0.56 regardless of AF status. Among patients without AF, a score ≥6 was associated with a 7.0% risk of cerebrovascular ischemic events. In patients with AF, the associated risk was lowest for patients with a CHA2DS2-VASc score of 1 (4.1%) and highest among those with a score of 5 (11.9%). Conclusion: In this nationwide cohort of intracerebral hemorrhage patients with or without AF, the risk of cerebrovascular ischemic events and mortality was substantial. The CHA2DS2-VASc score may be used for the estimation of stroke risk in patients sustaining an intracerebral hemorrhage, although its discriminative performance was poor.

Keywords:
Cerebrovascular events, Atrial fibrillation, Risk score, Epidemiology
1.
Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review.
Lancet Neurol
. 2009 Apr;8(4):355–69.
2.
van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis.
Lancet Neurol
. 2010 Feb;9(2):167–76.
3.
Lerario MP, Gialdini G, Lapidus DM, Shaw MM, Navi BB, Merkler AE, et al. Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation.
PLoS One
. 2015 Dec;10(12):e0145579.
4.
January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
J Am Coll Cardiol
. 2019 Jul;74(1):104–32.
5.
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J
. 2016 Oct;37(38):2893–962.
6.
Lip GY, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report.
Chest
. 2018 Nov;154(5):1121–201.
7.
Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
JAMA
. 2015 Sep;314(10):1030–8.
8.
Liu FD, Shen XL, Zhao R, Li GF, Wu YL, Tao XX, et al. Predictive role of CHADS2 and CHA2DS2-VASc scores on stroke and thromboembolism in patients without atrial fibrillation: a meta-analysis.
Ann Med
. 2016 Aug;48(5):367–75.
9.
Mitchell LB, Southern DA, Galbraith D, Ghali WA, Knudtson M, Wilton SB; APPROACH investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores.
Heart
. 2014 Oct;100(19):1524–30.
10.
Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.
Thromb Haemost
. 2018 Dec;118(12):2171–87.
11.
Schmidt M, Schmidt SA, Adelborg K, Sundbøll J, Laugesen K, Ehrenstein V, et al. The Danish health care system and epidemiological research: from health care contacts to database records.
Clin Epidemiol
. 2019 Jul;11:563–91.
12.
Johnsen SP, Ingeman A, Hundborg HH, Schaarup SZ, Gyllenborg J. The Danish Stroke Registry.
Clin Epidemiol
. 2016 Oct 25;8:697–702.
13.
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.
Stat Med
. 1999 Mar;18(6):695–706.
14.
Lindenstrøm E, Boysen G, Waage Christiansen L, à Rogvi Hansen B, Würtzen Nielsen P. Reliability of Scandinavian Neurological Stroke Scale.
Cerebrovasc Dis
. 1991;1(2):103–7.
15.
WHO MONICA Project Principal Investigators. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration.
J Clin Epidemiol
. 1988;41(2):105–14.
16.
Wildenschild C, Mehnert F, Thomsen RW, Iversen HK, Vestergaard K, Ingeman A, et al. Registration of acute stroke: validity in the Danish Stroke Registry and the Danish National Registry of Patients.
Clin Epidemiol
. 2013 Dec;6:27–36.
17.
Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential.
Clin Epidemiol
. 2015 Nov;7:449–90.
18.
Korompoki E, Filippidis FT, Nielsen PB, Del Giudice A, Lip GY, Kuramatsu JB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation.
Neurology
. 2017 Aug;89(7):687–96.
19.
Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time.
Stat Med
. 2007 Oct;26(24):4505–19.
20.
Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations.
Stata J
. 2010;10(3):408–22.
21.
Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker.
Biometrics
. 2000 Jun;56(2):337–44.
22.
Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study.
Sci Rep
. 2016 Jun;6(1):27410.
23.
Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study.
Circulation
. 2015 Aug;132(6):517–25.
24.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
Chest
. 2010 Feb;137(2):263–72.
25.
Chen JY, Zhang AD, Lu HY, Guo J, Wang FF, Li ZC. CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis.
J Geriatr Cardiol
. 2013 Sep;10(3):258–66.
26.
Lip GY, Skjøth F, Rasmussen LH, Nielsen PB, Larsen TB. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
J Am Coll Cardiol
. 2015 Jul;66(4):488–90.
27.
Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making.
Thromb Haemost
. 2017 Jun;117(7):1230–9.
28.
Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage.
J Neurol Neurosurg Psychiatry
. 2007 Aug;78(8):836–40.
29.
Poon MT, Fonville AF, Al-Shahi Salman R. Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis.
J Neurol Neurosurg Psychiatry
. 2014 Jun;85(6):660–7.
30.
van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, et al.; APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
Trials
. 2015 Sep;16(1):393.
31.
Charidimou A, Wilson D, Shakeshaft C, Ambler G, White M, Cohen H, et al. The Clinical Relevance of Microbleeds in Stroke study (CROMIS-2): rationale, design, and methods.
Int J Stroke
. 2015 Oct;10Suppl A100:155–61.
32.
Shoamanesh A. NASPAF-ICH: NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH [Internet]. ClinicalTrials.gov. 2018 [cited 2017 Dec 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02998905.
33.
Wilson D, Ambler G, Shakeshaft C, Brown MM, Charidimou A, Al-Shahi Salman R, et al.; CROMIS-2 collaborators. Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study.
Lancet Neurol
. 2018 Jun;17(6):539–47.
34.
Savino JA 3rd, Halperin JL. Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? The CHA2 DS2-VASc 1 Conundrum: Decision Making at the Lower End of the Risk Spectrum.
Circulation
. 2016 Apr;133(15):1504–11; discussion 1511.
35.
Lip GY, Nielsen PB. Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA2DS2-VASc Score 1 in Men, 2 in Women) Be Anticoagulated? Yes: Even 1 Stroke Risk Factor Confers a Real Risk of Stroke.
Circulation
. 2016 Apr;133(15):1498–503.
36.
Johnsen SP, Ingeman A, Hundborg HH, Schaarup SZ, Gyllenborg J. The Danish Stroke Registry.
Clin Epidemiol
. 2016 Oct;8:697–702.
37.
Rix TA, Riahi S, Overvad K, Lundbye-Christensen S, Schmidt EB, Joensen AM. Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry.
Scand Cardiovasc J
. 2012 Jun;46(3):149–53.
38.
Chao TF, Lip GY, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
Eur Heart J
. 2019 May;40(19):1504–14.
39.
Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study.
Thromb Haemost
. 2018 Jul;118(7):1296–304.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.